-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is from NEJM Journal Watch
Subcutaneous Foslevodopa-Foscarbidopa for Advanced Parkinson Disease
Subcutaneous infusion of foslevodopa-foscarbidopa for advanced Parkinson's disease
Reviewed by Michael S.
Okun, MD
Compared with oral levodopa-carbidopa, continuous subcutaneous infusion of foslevodopa-foscarbidopa significantly improved daily "on" and "off" times
.
in patients with advanced Parkinson's disease (PD).
。 To evaluate the safety and efficacy of this therapy, investigators in the United States and Australia conducted an industry-funded multicenter, randomized, double-blind, double-mimicry, active-drug-controlled Phase 3 study that divided 141 patients with advanced PD (mean daily "off" time ≥ 2.
5 hours) into two groups, one with continuous subcutaneous infusion of foslevodopa-foscarbidopa and oral placebo, and the other with continuous subcutaneous infusion with placebo and oral levodopa-carbidopa
。
After 12 weeks of treatment, there was a significantly larger increase in mean 'opening' time in patients with continuous subcutaneous foslevodopa-foscarbidopa infusion without bothersome dyskinesia compared with those with oral levodopa-carbidopa (primary outcome; 2.
72 hours vs.
0.
97 hours/day; P=0.
0083), with a significantly larger reduction in mean "off" time (2.
75 hours/day vs.
0.
96 hours/day; P=0.
0054）
。 The most common adverse events (mostly mild to moderate) in the Foslevodopa-Foscarbidopa group were redness at the infusion site (27%), pain (26%), cellulitis (19%), and edema (12%); One patient developed catheter site cellulitis and one patient developed infusion site cellulitis
.
comments
The field has long been waiting for levodopa and carbidopa prodrugs
that can be infused subcutaneously.
If approved by the US FDA, the therapy would add a new treatment option for patients with Parkinson's disease that could be considered
before adopting more invasive therapies such as duodenal catheterization with a Dodopa pump, deep brain stimulation, or brain ablation.
Articles that were commented on
Soileau MJ et al.
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: A randomised, double-blind, active-controlled, phase 3 trial.
Lancet Neurol 2022 Dec; 21:1099.
(https://doi.
org/10.
1016/S1474-4422(22)00400-8)
A collection of NEJM journals
NEJM Journal Watch is published by NEJM Group, inviting internationally renowned doctors to review important papers in the field of medicine and help doctors understand and apply the latest progress.
"NEJM Medical Frontiers" is translated several times a week, published on the app and official website, and 2-3 selected articles are published
on WeChat.
Copyright InformationThis article was translated, written or commissioned by Jiahui Medical Research and Education Group (J-Med) in collaboration with the New England Journal of Medicine (NEJM) for NEJM Medical Frontiers
.
The full text of the Chinese translation and the figures contained therein are exclusively licensed
by NEJM Group.
If you want to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement and the copyright owner reserves the right to
pursue legal liability.
